NASDAQ:AGLE

Aeglea BioTherapeutics Competitors

$8.17
+0.22 (+2.77 %)
(As of 04/16/2021 12:00 AM ET)
Add
Compare
Today's Range
$7.82
Now: $8.17
$8.25
50-Day Range
$7.08
MA: $7.76
$8.57
52-Week Range
$4.91
Now: $8.17
$11.38
Volume182,213 shs
Average Volume212,453 shs
Market Capitalization$392.29 million
P/E RatioN/A
Dividend YieldN/A
Beta1.66

Competitors

Aeglea BioTherapeutics (NASDAQ:AGLE) Vs. QURE, TVTX, IMGN, PRLD, AMTI, and OLMA

Should you be buying AGLE stock or one of its competitors? Companies in the industry of "pharmaceutical preparations" are considered alternatives and competitors to Aeglea BioTherapeutics, including uniQure (QURE), Travere Therapeutics (TVTX), ImmunoGen (IMGN), Prelude Therapeutics (PRLD), Applied Molecular Transport (AMTI), and Olema Pharmaceuticals (OLMA).

uniQure (NASDAQ:QURE) and Aeglea BioTherapeutics (NASDAQ:AGLE) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their analyst recommendations, dividends, institutional ownership, profitability, risk, valuation and earnings.

Volatility & Risk

uniQure has a beta of 1.19, meaning that its share price is 19% more volatile than the S&P 500. Comparatively, Aeglea BioTherapeutics has a beta of 1.66, meaning that its share price is 66% more volatile than the S&P 500.

Profitability

This table compares uniQure and Aeglea BioTherapeutics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
uniQure-2,738.33%-59.64%-41.47%
Aeglea BioTherapeuticsN/A-81.42%-66.88%

Institutional and Insider Ownership

78.3% of uniQure shares are owned by institutional investors. Comparatively, 80.9% of Aeglea BioTherapeutics shares are owned by institutional investors. 2.8% of uniQure shares are owned by company insiders. Comparatively, 13.7% of Aeglea BioTherapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Earnings and Valuation

This table compares uniQure and Aeglea BioTherapeutics' revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
uniQure$7.28 million210.57$-124,200,000.00($3.11)-10.95
Aeglea BioTherapeutics$3.89 million100.85$-78,250,000.00($2.45)-3.33

Aeglea BioTherapeutics has lower revenue, but higher earnings than uniQure. uniQure is trading at a lower price-to-earnings ratio than Aeglea BioTherapeutics, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a breakdown of recent recommendations and price targets for uniQure and Aeglea BioTherapeutics, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
uniQure011113.00
Aeglea BioTherapeutics00403.00

uniQure presently has a consensus price target of $68.4615, indicating a potential upside of 100.94%. Aeglea BioTherapeutics has a consensus price target of $12.6667, indicating a potential upside of 55.04%. Given uniQure's higher probable upside, equities analysts plainly believe uniQure is more favorable than Aeglea BioTherapeutics.

Travere Therapeutics (NASDAQ:TVTX) and Aeglea BioTherapeutics (NASDAQ:AGLE) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their analyst recommendations, institutional ownership, earnings, valuation, profitability, risk and dividends.

Volatility and Risk

Travere Therapeutics has a beta of 0.77, indicating that its stock price is 23% less volatile than the S&P 500. Comparatively, Aeglea BioTherapeutics has a beta of 1.66, indicating that its stock price is 66% more volatile than the S&P 500.

Profitability

This table compares Travere Therapeutics and Aeglea BioTherapeutics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Travere Therapeutics-40.24%-29.27%-12.25%
Aeglea BioTherapeuticsN/A-81.42%-66.88%

Institutional and Insider Ownership

80.9% of Aeglea BioTherapeutics shares are owned by institutional investors. 4.6% of Travere Therapeutics shares are owned by insiders. Comparatively, 13.7% of Aeglea BioTherapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Valuation & Earnings

This table compares Travere Therapeutics and Aeglea BioTherapeutics' top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Travere Therapeutics$175.34 million8.60$-146,430,000.00($3.46)-7.21
Aeglea BioTherapeutics$3.89 million100.85$-78,250,000.00($2.45)-3.33

Aeglea BioTherapeutics has lower revenue, but higher earnings than Travere Therapeutics. Travere Therapeutics is trading at a lower price-to-earnings ratio than Aeglea BioTherapeutics, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a summary of current ratings and price targets for Travere Therapeutics and Aeglea BioTherapeutics, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Travere Therapeutics00503.00
Aeglea BioTherapeutics00403.00

Travere Therapeutics currently has a consensus target price of $44.3333, indicating a potential upside of 77.69%. Aeglea BioTherapeutics has a consensus target price of $12.6667, indicating a potential upside of 55.04%. Given Travere Therapeutics' higher probable upside, research analysts plainly believe Travere Therapeutics is more favorable than Aeglea BioTherapeutics.

Summary

Aeglea BioTherapeutics beats Travere Therapeutics on 8 of the 13 factors compared between the two stocks.

ImmunoGen (NASDAQ:IMGN) and Aeglea BioTherapeutics (NASDAQ:AGLE) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their analyst recommendations, institutional ownership, earnings, valuation, profitability, risk and dividends.

Volatility and Risk

ImmunoGen has a beta of 1.65, indicating that its stock price is 65% more volatile than the S&P 500. Comparatively, Aeglea BioTherapeutics has a beta of 1.66, indicating that its stock price is 66% more volatile than the S&P 500.

Profitability

This table compares ImmunoGen and Aeglea BioTherapeutics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
ImmunoGen-77.65%N/A-26.98%
Aeglea BioTherapeuticsN/A-81.42%-66.88%

Institutional and Insider Ownership

73.0% of ImmunoGen shares are owned by institutional investors. Comparatively, 80.9% of Aeglea BioTherapeutics shares are owned by institutional investors. 3.8% of ImmunoGen shares are owned by insiders. Comparatively, 13.7% of Aeglea BioTherapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Valuation & Earnings

This table compares ImmunoGen and Aeglea BioTherapeutics' top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
ImmunoGen$82.27 million18.26$-104,130,000.00($0.70)-10.74
Aeglea BioTherapeutics$3.89 million100.85$-78,250,000.00($2.45)-3.33

Aeglea BioTherapeutics has lower revenue, but higher earnings than ImmunoGen. ImmunoGen is trading at a lower price-to-earnings ratio than Aeglea BioTherapeutics, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a summary of current ratings and price targets for ImmunoGen and Aeglea BioTherapeutics, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
ImmunoGen03402.57
Aeglea BioTherapeutics00403.00

ImmunoGen currently has a consensus target price of $10.10, indicating a potential upside of 34.31%. Aeglea BioTherapeutics has a consensus target price of $12.6667, indicating a potential upside of 55.04%. Given Aeglea BioTherapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Aeglea BioTherapeutics is more favorable than ImmunoGen.

Summary

Aeglea BioTherapeutics beats ImmunoGen on 9 of the 13 factors compared between the two stocks.

Prelude Therapeutics (NASDAQ:PRLD) and Aeglea BioTherapeutics (NASDAQ:AGLE) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their analyst recommendations, institutional ownership, earnings, valuation, profitability, risk and dividends.

Profitability

This table compares Prelude Therapeutics and Aeglea BioTherapeutics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Prelude TherapeuticsN/AN/AN/A
Aeglea BioTherapeuticsN/A-81.42%-66.88%

Institutional and Insider Ownership

76.2% of Prelude Therapeutics shares are owned by institutional investors. Comparatively, 80.9% of Aeglea BioTherapeutics shares are owned by institutional investors. 13.7% of Aeglea BioTherapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Valuation & Earnings

This table compares Prelude Therapeutics and Aeglea BioTherapeutics' top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Prelude TherapeuticsN/AN/AN/AN/AN/A
Aeglea BioTherapeutics$3.89 million100.85$-78,250,000.00($2.45)-3.33

Prelude Therapeutics has higher earnings, but lower revenue than Aeglea BioTherapeutics.

Analyst Ratings

This is a summary of current ratings and price targets for Prelude Therapeutics and Aeglea BioTherapeutics, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Prelude Therapeutics03102.25
Aeglea BioTherapeutics00403.00

Prelude Therapeutics currently has a consensus target price of $54.25, indicating a potential upside of 68.27%. Aeglea BioTherapeutics has a consensus target price of $12.6667, indicating a potential upside of 55.04%. Given Prelude Therapeutics' higher probable upside, research analysts plainly believe Prelude Therapeutics is more favorable than Aeglea BioTherapeutics.

Summary

Aeglea BioTherapeutics beats Prelude Therapeutics on 5 of the 8 factors compared between the two stocks.

Applied Molecular Transport (NASDAQ:AMTI) and Aeglea BioTherapeutics (NASDAQ:AGLE) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their analyst recommendations, institutional ownership, earnings, valuation, profitability, risk and dividends.

Analyst Ratings

This is a summary of current ratings and price targets for Applied Molecular Transport and Aeglea BioTherapeutics, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Applied Molecular Transport00403.00
Aeglea BioTherapeutics00403.00

Applied Molecular Transport currently has a consensus target price of $68.75, indicating a potential upside of 64.32%. Aeglea BioTherapeutics has a consensus target price of $12.6667, indicating a potential upside of 55.04%. Given Applied Molecular Transport's higher probable upside, research analysts plainly believe Applied Molecular Transport is more favorable than Aeglea BioTherapeutics.

Profitability

This table compares Applied Molecular Transport and Aeglea BioTherapeutics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Applied Molecular TransportN/AN/AN/A
Aeglea BioTherapeuticsN/A-81.42%-66.88%

Valuation & Earnings

This table compares Applied Molecular Transport and Aeglea BioTherapeutics' top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Applied Molecular TransportN/AN/A$-28,040,000.00N/AN/A
Aeglea BioTherapeutics$3.89 million100.85$-78,250,000.00($2.45)-3.33

Applied Molecular Transport has higher earnings, but lower revenue than Aeglea BioTherapeutics.

Institutional and Insider Ownership

52.0% of Applied Molecular Transport shares are owned by institutional investors. Comparatively, 80.9% of Aeglea BioTherapeutics shares are owned by institutional investors. 13.7% of Aeglea BioTherapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Summary

Applied Molecular Transport beats Aeglea BioTherapeutics on 4 of the 7 factors compared between the two stocks.

Aeglea BioTherapeutics (NASDAQ:AGLE) and Olema Pharmaceuticals (NASDAQ:OLMA) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their valuation, dividends, analyst recommendations, institutional ownership, earnings, risk and profitability.

Analyst Recommendations

This is a breakdown of current ratings and recommmendations for Aeglea BioTherapeutics and Olema Pharmaceuticals, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Aeglea BioTherapeutics00403.00
Olema Pharmaceuticals00403.00

Aeglea BioTherapeutics currently has a consensus target price of $12.6667, indicating a potential upside of 55.04%. Olema Pharmaceuticals has a consensus target price of $60.6667, indicating a potential upside of 67.87%. Given Olema Pharmaceuticals' higher probable upside, analysts clearly believe Olema Pharmaceuticals is more favorable than Aeglea BioTherapeutics.

Profitability

This table compares Aeglea BioTherapeutics and Olema Pharmaceuticals' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Aeglea BioTherapeuticsN/A-81.42%-66.88%
Olema PharmaceuticalsN/AN/AN/A

Valuation and Earnings

This table compares Aeglea BioTherapeutics and Olema Pharmaceuticals' top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Aeglea BioTherapeutics$3.89 million100.85$-78,250,000.00($2.45)-3.33
Olema PharmaceuticalsN/AN/AN/AN/AN/A

Olema Pharmaceuticals has lower revenue, but higher earnings than Aeglea BioTherapeutics.

Institutional & Insider Ownership

80.9% of Aeglea BioTherapeutics shares are owned by institutional investors. 13.7% of Aeglea BioTherapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.


Aeglea BioTherapeutics Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
uniQure logo
QURE
uniQure
1.7$34.07+4.1%$1.53 billion$7.28 million-9.04Insider Selling
Travere Therapeutics logo
TVTX
Travere Therapeutics
1.2$24.95+4.0%$1.51 billion$175.34 million-14.68Analyst Downgrade
Analyst Revision
News Coverage
ImmunoGen logo
IMGN
ImmunoGen
1.5$7.52+2.4%$1.50 billion$82.27 million-18.34
Prelude Therapeutics logo
PRLD
Prelude Therapeutics
1.4$32.24+5.2%$1.50 billionN/A0.00Analyst Upgrade
News Coverage
Applied Molecular Transport logo
AMTI
Applied Molecular Transport
2.0$41.84+3.6%$1.47 billionN/A0.00
OLMA
Olema Pharmaceuticals
1.6$36.14+2.1%$1.45 billionN/A0.00Increase in Short Interest
News Coverage
PMV Pharmaceuticals logo
PMVP
PMV Pharmaceuticals
1.4$32.37+0.9%$1.45 billionN/A0.00Insider Selling
Increase in Short Interest
Endo International logo
ENDP
Endo International
1.3$6.26+3.4%$1.44 billion$2.91 billion-9.21
Cara Therapeutics logo
CARA
Cara Therapeutics
1.6$28.51+0.7%$1.42 billion$19.89 million-13.45Analyst Report
News Coverage
Theravance Biopharma logo
TBPH
Theravance Biopharma
1.6$21.71+1.0%$1.42 billion$73.41 million-4.59
Zealand Pharma A/S logo
ZEAL
Zealand Pharma A/S
1.2$32.56+0.8%$1.41 billion$6.20 million-14.28News Coverage
Zymeworks logo
ZYME
Zymeworks
1.8$30.38+0.7%$1.40 billion$29.54 million-8.06Unusual Options Activity
Cassava Sciences logo
SAVA
Cassava Sciences
0.9$34.85+0.7%$1.39 billionN/A-145.21
Aclaris Therapeutics logo
ACRS
Aclaris Therapeutics
0.8$26.68+1.3%$1.38 billion$4.23 million-19.76Increase in Short Interest
ATBPD
Antibe Therapeutics
0.1$3.57+0.3%$1.38 billion$7.51 million-5.95Gap Down
Arcutis Biotherapeutics logo
ARQT
Arcutis Biotherapeutics
1.6$27.52+4.2%$1.38 billionN/A-2.98
Keros Therapeutics logo
KROS
Keros Therapeutics
1.6$56.67+12.0%$1.32 billionN/A0.00Increase in Short Interest
COMPASS Pathways logo
CMPS
COMPASS Pathways
1.5$34.35+0.9%$1.26 billionN/A0.00Analyst Upgrade
News Coverage
Shattuck Labs logo
STTK
Shattuck Labs
1.5$30.01+5.6%$1.25 billionN/A0.00Analyst Report
Increase in Short Interest
Repare Therapeutics logo
RPTX
Repare Therapeutics
1.6$33.68+1.1%$1.25 billionN/A0.00
Dynavax Technologies logo
DVAX
Dynavax Technologies
1.7$10.99+1.2%$1.24 billion$35.22 million-8.02News Coverage
Ocular Therapeutix logo
OCUL
Ocular Therapeutix
1.6$15.89+1.6%$1.21 billion$4.23 million-8.88
Kronos Bio logo
KRON
Kronos Bio
1.7$21.56+0.7%$1.21 billionN/A0.00Insider Selling
Innoviva logo
INVA
Innoviva
1.4$11.90+0.1%$1.21 billion$261.02 million6.07
Avid Bioservices logo
CDMO
Avid Bioservices
1.7$19.16+1.7%$1.17 billion$59.70 million-191.60
Protagonist Therapeutics logo
PTGX
Protagonist Therapeutics
1.5$26.55+0.3%$1.16 billion$230,000.00-12.35
Phathom Pharmaceuticals logo
PHAT
Phathom Pharmaceuticals
1.8$37.01+0.0%$1.16 billionN/A-2.65
Mersana Therapeutics logo
MRSN
Mersana Therapeutics
1.2$16.65+3.7%$1.15 billion$42.12 million-12.33Unusual Options Activity
NKTX
Nkarta
1.8$34.87+5.2%$1.14 billionN/A0.00Increase in Short Interest
Y-mAbs Therapeutics logo
YMAB
Y-mAbs Therapeutics
1.6$26.22+4.1%$1.14 billionN/A-8.83Insider Selling
Increase in Short Interest
Omeros logo
OMER
Omeros
1.4$18.37+0.2%$1.14 billion$111.81 million-7.72
Stoke Therapeutics logo
STOK
Stoke Therapeutics
1.4$30.91+6.5%$1.13 billionN/A-17.17
Pliant Therapeutics logo
PLRX
Pliant Therapeutics
1.9$29.93+2.4%$1.07 billion$57.05 million0.00Insider Selling
Constellation Pharmaceuticals logo
CNST
Constellation Pharmaceuticals
1.2$22.29+4.5%$1.07 billionN/A-8.23Unusual Options Activity
Kiniksa Pharmaceuticals logo
KNSA
Kiniksa Pharmaceuticals
1.7$15.63+5.2%$1.07 billionN/A-6.59
Arcturus Therapeutics logo
ARCT
Arcturus Therapeutics
1.6$40.33+2.0%$1.06 billion$20.79 million-13.91
Zogenix logo
ZGNX
Zogenix
1.7$19.00+3.5%$1.06 billion$3.65 million-2.00Analyst Upgrade
News Coverage
Praxis Precision Medicines logo
PRAX
Praxis Precision Medicines
1.7$27.37+5.6%$1.06 billionN/A0.00Increase in Short Interest
Lockup Expiration
News Coverage
MannKind logo
MNKD
MannKind
1.4$4.18+2.9%$1.04 billion$63.04 million-19.90Increase in Short Interest
Trillium Therapeutics logo
TRIL
Trillium Therapeutics
1.7$9.98+4.0%$1.03 billion$120,000.00-3.70Analyst Report
Enanta Pharmaceuticals logo
ENTA
Enanta Pharmaceuticals
1.4$50.68+2.1%$1.02 billion$122.47 million-27.85Analyst Downgrade
News Coverage
Prothena logo
PRTA
Prothena
2.1$24.85+3.2%$994.15 million$810,000.00-9.71Increase in Short Interest
News Coverage
Rhythm Pharmaceuticals logo
RYTM
Rhythm Pharmaceuticals
1.8$19.71+5.2%$989.07 millionN/A-6.48Increase in Short Interest
Phibro Animal Health logo
PAHC
Phibro Animal Health
1.8$24.43+1.1%$988.27 million$800.40 million23.05
G1 Therapeutics logo
GTHX
G1 Therapeutics
1.5$23.51+6.8%$986.46 millionN/A-8.11Insider Selling
Syndax Pharmaceuticals logo
SNDX
Syndax Pharmaceuticals
1.6$20.41+2.8%$984.50 million$1.52 million-10.86Increase in Short Interest
Akero Therapeutics logo
AKRO
Akero Therapeutics
1.7$27.34+1.0%$950.61 millionN/A-12.60
Radius Health logo
RDUS
Radius Health
1.1$19.71+0.2%$924.28 million$173.32 million-8.08
Vanda Pharmaceuticals logo
VNDA
Vanda Pharmaceuticals
1.5$16.67+0.7%$914.90 million$227.19 million46.31Analyst Upgrade
Dyne Therapeutics logo
DYN
Dyne Therapeutics
1.6$17.45+0.5%$897.94 millionN/A0.00
This page was last updated on 4/16/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.